Why the study?
Does sodium 5-hydroxydecanoate block the anti-ischemic actions of cromakalim in isolated rat hearts?
Population
Isolated globally ischemic rat hearts, phenylephrine-contracted rat aorta, guinea pig papillary muscle, and…
Comparison
Sodium 5-hydroxydecanoate or glibenclamide added… vs Cromakalim alone
Design
Preclinical
Follow-up
30 minutes of reperfusion
Authors
Loading...
May enable ischemia-selective cardioprotection without nonischemic effects; hypothesis-generating for KATP modulation pending in vivo and clinical validation.
Does sodium 5-hydroxydecanoate block the anti-ischemic actions of cromakalim in isolated rat hearts?
Sodium 5-hydroxydecanoate acts as an ischemia-selective inhibitor of ATP-sensitive potassium channels, blocking the cardioprotective effects of cromakalim without affecting nonischemic tissues.
McCullough et al. (1991) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: